Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Publisher's site:
http://dx.doi.org/10.15585/mmwr.mm6728a2
Personal Author:
Hutin, Yvan ; Nasrullah, Muazzam ; Easterbrook, Philippa ; Nguimfack, Boniface Dongmo ; Burrone, Esteban ; ... More +
Hutin, Yvan ; Nasrullah, Muazzam ; Easterbrook, Philippa ; Nguimfack, Boniface Dongmo ; Burrone, Esteban ; Averhoff, Francisco ; Bulterys, Marc Less -
Corporate Authors:
National Center for HIV, Viral Hepatitis, STD, and TB Prevention (U.S.)Division of Viral Hepatitis.
Description:
Worldwide, an estimated 257 million persons are living with chronic hepatitis B Virus (HBV) infection (1). To achieve the World Health Organization (WHO) goals for elimination of HBV infection Worldwide by 2030, defined by WHO as 90% reduction in incidence and 65% reduction in Mortality, access to treatment will be crucial. WHO estimated the care cascade* for HBV infection, globally and by WHO Region. The patent and licensing status of entecavir and tenofovir, two WHO-recommended medicines for HBV treatment, were examined using the Medicines Patent Pool MedsPaL| database. The international price of tenofovir was estimated using WHO's global price reporting mechanism (GPRM), and for entecavir from a published study (2). In 2016, among the estimated 257 million persons infected with HBV Worldwide, approximately 27 million (10.5%) were aware of their infection, an estimated 4.5 million (16.7%) of whom were on treatment. In 2017, all low- and middle-income countries (LMICs) could legally procure generic entecavir, and all but two LMICs could legally procure generic tenofovir. The median price of WHO-prequalified generic tenofovir on the international market fell from $208 per year in 2004 to $32 per year in 2016. In 2015, the lowest reported price of entecavir was $427 per year of treatment (2). Increased availability of generic antivirals effective in treating chronic HBV infection has likely improved access to treatment. Taking advantage of reductions in price of antivirals active against HBV infection could further increase access to treatment. Regular Analysis of the hepatitis B treatment care cascade can assist in monitoring progress toward HBV elimination goals.
Subjects:
[+]
Full Report Global Health Health Services Accessibility Hepatitis B Humans
Source:
MMWR Morb Mortal Wkly Rep. 67(28):773-777.
Pubmed ID:
30025413
Pubmed Central ID:
PMC6054001
Document Type:
Journal Article
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:fe43008ee873b8144d64decb0f0c56259cad25111fadf641a00f421e4fde1a69
Download URL:
https://stacks.cdc.gov/view/cdc/58430/cdc_58430_DS1.pdf
File Type:

Supporting Files

• 	mm6728a2-F1.gif	gif
  	mm6728a2-F1.jpg	jpeg
  	mm6728a2-F2.gif	gif
  	mm6728a2-F2.jpg	jpeg
  	mm6728a2-F3.gif	gif
  	mm6728a2-F3.jpg	jpeg
  	mm6728a2.nxml	xml

More +